Go inside the room of our closed-door session on solutions for the drug-pricing dilemma. It included panelists from three essential perspectives: pharma, payers, and patients.
Even if we eliminated all use of antibiotics in animals and all unnecessary use in humans, we still are bound by a pathetic pipeline to combat what we’re facing now.
Our shared goal should be to design an economically sustainable system that ensures patient access and promotes future innovation. Here are a few keys to consider as we work toward this goal.
Cerulean Pharma’s business plan is, of course, contingent upon further progress in the clinic, but if that happens, the company may just propel us into an era of the independent, commercially successful nanopharmaceutical company.
Executives from Merial (the animal health division of Sanofi) and Zoetis discuss why the financial community is considering the animal health industry a promising short- and long-term investment opportunity.
With life sciences companies looking to grow their pipelines, they are reaching beyond their own R&D programs to seek technologies and products from external startups in need of funding. Big Pharmas such as J&J are relying on their VC funds to secure innovation.
As head of global information for a major biopharmaceutical company, I try to anticipate what might be the next service line that we should provide to our internal customers and what might be the next big thing in terms of information provision, rights requirements, and the like. To ensure that my corporate information center runs optimally, there are five areas of improvement I continue to focus on, which not only keeps my team current, highly-skilled, collaborative and empowered, but also demonstrates a positive ROI for our parent organization.
As part of the selection process of CMOs and strategic suppliers, three issues related to operations deserve particular attention: Compliance, Consistency, and Resilience.
Millennials, the single largest demographic in the workplace today, are often derided as lazy, disrespectful, and needy. They’re also criticized as being so addicted to technology that they email and text message information that should be communicated face-to-face to supervisors and coworkers.
When a pharma is divesting an asset, how important is it to take the asset and the people (i.e., the champions and asset experts) when determining your capital allocation? When do you say that the people have to be included, and what are some of the considerations on the intellectual capital, besides the actual product?
Can Biopharma Jump The S Curve: Part 4 of 4
At a recent conference I overheard a VC admit that a few years ago if a biotech startup approached their company with an idea, no matter how good the data might seems, if it involved Alzheimer’s disease, his company was not interested in backing it.
Suresh Kumar, EVP of external affairs, “Sanofi EVP Weighs In On The Politics Of Drug Pricing,” chaired an Responding to Ebola panelat Davos (i.e., the World Economic Forum’s Annual Meeting, held in Davos-Klosters, Switzerland) in 2015, he found the experience enlightening. “
The first time I sat down for a conversation with Peter Hecht, CEO and cofounder of Ironwood Pharmaceuticals toward developing the March 2016 Life Science Leader magazine cover feature, he prefaced responding to my first question by saying, “In general, I’m not a big fan of the ‘Great Man’ theory of history.
Merck recently announced its plans to lay off R&D workers at three East Coast sites; a move that will supposedly affect less than 10 percent of discovery, preclinical, and early development employees in Kenilworth and Rahway, N.J., and North Wales, PA.
Life Science Leader Launches a Search for Common Ground